Monte Rosa Therapeutics develops small molecule drugs that break down proteins tied to immune disorders and cancers. GLUE reports earnings on Thu, Nov 5, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 6 firms (6 buy, 0 hold, 0 sell).
Prices, price targets and earnings estimates for GLUE are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
No whale options trades in GLUE in the last 90 days.
Total alerts
0
Bullish
0
0%
Bearish
0
0%
Date span
—
Loading…
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GLUE is in one of them and how their past GLUE trades turned out.
Monte Rosa Therapeutics is a biotechnology company based in Boston, Massachusetts. It develops small molecule drugs called molecular glue degraders, which use the body's natural protein disposal system to break down proteins tied to disease. Its candidates are in clinical trials for immune conditions, inflammatory diseases, and prostate cancer, and it is developing programs for other cancers. Its main partner is Novartis, which has licensed one of its immune disease programs.
